Osteoporosis is a disorder associated with a decrease in BMD, low bone mass and increased bone fragility; individuals with osteoporosis are at an increased risk of fragility fractures. The economic and societal burden of fragility fractures is massive, previously estimated at 37 billion euros per year in 27 European countries alone
1
, and is set to rise owing to an increasing skew towards an older population 2, 3 . Importantly, the ability to predict those at risk has developed enormously over the past 20 years through the use of fracture prediction tools and an increasing understanding of scanning modalities, such as dual-energy X-ray absorptiometry (DXA). Despite this, a treatment gap exists between those at risk of fracture and those receiving treatment for the prevention of fragility fractures.
In this Review, we expand on the current epidemiology of fragility fractures, provide an up-to-date definition of osteoporosis and discuss the widening gap in treatment for those at risk. We also highlight the development of fracture prediction tools and the benefits they have brought in identifying those at risk, with particular focus on the recent Screening of Older Women for the Prevention of Fractures (SCOOP) trial. We then discuss the role of DXA in enhancing the identification of individuals at risk of fracture and examine more recent imaging modalities and analyses.
The epidemiology of fractures
Fractures are a major concern for the health of individuals and the general population at large, with common fragility fracture sites being found in the hip, spine and wrist. In 2010 in Europe, there were 22 million women and 5.5 million men with osteoporosis, accounting for 2% of the overall burden of non-communicable diseases 1 . This population experienced an estimated 3.5 million fragility fractures, with 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1.8 million 'other fractures' (comprising fractures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula and sternum and other femoral fractures) 1 . In the USA, one in two women experience osteoporosis-related fractures after menopause 4 . In the UK, there are an estimated 200,000 osteoporosis-related fractures per year 5 . These fractures severely effect quality of life, with 50% of patients with hip fracture losing the ability to live independently 6 . In the USA, fragility fractures are responsible for >432,000 admissions to hospital and 180,000 admissions to nursing homes each year 7 .
Incidence, mortality and economic cost. The incidences of age-specific vertebral, forearm and hip fractures are increasing owing to the elderly population being the fastest growing age demographic 1, 8, 9 . Although the incidence of fragility fractures continues to rise in transitioning populations, notably, the rate of hip fracture has stabilized in many resource-rich countries 10 ( Fig. 1) , and wide global variation exists by geography 11 , ethnicity and socio-economic status 12 .
The mortality associated with major osteoporotic fractures is substantial, with 20% mortality from hip fractures within the first year 13, 14 . Moreover, hip fractures
Major osteoporotic fractures
Fractures attributable to osteoporosis including hip, forearm, humerus or clinically presenting vertebral fractures.
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result in 20% of orthopaedic bed occupancy in the UK, and the mean in-hospital stay is 27 days. The annual economic cost of fragility fractures in Europe was estimated at €37 billion 1 , with 66% of the cost attributable to incident fractures, 29% to prevalent fractures and 5% to associated pharmacological costs. In the USA alone, the cost of fragility fractures in 2005 was estimated to be $17 billion, with a subsequent increase to $25.3 billion estimated by 2025 (reF. 15 ). A shift in the demographic landscape of fractures has occurred, which is associated with the increasingly elderly skew of the population 16 ; therefore, the above costs might increase further. As such, more recent health economic analyses are required to elucidate the modern day financial impact of fragility fractures.
Medical interventions for osteoporosis. The past 20 years have seen marked developments in medical interventions for osteoporosis including calcium and vitamin D supplementation, hormonal replacement therapy and bisphosphonates 1, 17 . These pharmaceutical therapies reduce the incidence of osteoporotic fractures [18] [19] [20] [21] [22] . For example, bisphosphonates decrease all fractures by 35%, non-vertebral fractures by ~25% and vertebral fractures by 50% 20, 23 . In addition, denosumab has been shown in a trial to reduce fracture rates after 10 years of treatment 24 . Notably, in this trial, vertebral fracture yearly incidence in the denosumab treatment group (females aged 60-90 years) remained at a similar rate during the trial extension (to 10 years) to that seen in the original trial (3 years): vertebral fractures at 0.9-1.9% and non-vertebral fractures at 0.8-2.6%. This yearly incidence was lower than that observed in a virtual placebo group, and both efficacy and safety surveillance are ongoing. Since 2015, bone-forming agents such as teriparatide 25, 26 and abaloparatide 27, 28 have shown good efficacy in randomized controlled trials.
The osteoporosis treatment gap. A major concern in the management of osteoporosis is that a minority of patients receive treatment 1, 29 . This untreated population is referred to as the osteoporosis treatment gap 30 , which refers to the difference between the number of individuals who are at high risk of fracture and the proportion of these people who receive fracture preventive interventions. An unfortunate reality of the treatment gap in osteoporosis is that, of the individuals who sustain a fragility fracture, <20% receive secondary preventive treatment, with this proportion being even lower in older females and patients in long-term care. Fracture assessment tools, which utilize clinical variables to provide a measure of fracture risk, have therefore been developed and will be discussed later 31, 32 . Globally, marked variation exists in the use of fracture assessment tools, with 1,000-fold variation in tool use worldwide despite far lower variation in fracture rates 33 . This paucity of tool use could be attributable to a lack of coherent local guidelines or difficulty accessing the tools online or even in paper format 34 . Beyond the variation in assessment of fracture risk, some resourcerich countries, including the UK and USA, have shown a concerning downward trend in treatment of osteoporosis 35, 36 . In the USA, this observation might be due to changes in the provision of medical reimbursement. Moreover, in the UK and USA, increasing concern exists regarding adverse events related to bisphosphonates, which have been hyped in the lay media 37 . This concern is countered by a Danish study, which demonstrated that, even in individuals who were overtreated with 10 years of the bisphosphonate alendronate, the fracture risk was lower than in age-matched controls 38, 39 . Progress in the effective identification of high-risk individuals has depended upon the definition of osteoporosis, the development of fracture risk prediction tools and an understanding of imaging modalities for assessing bone parameters, all of which are discussed below.
Diagnosis of osteoporosis
A step-change in the assessment of bone fragility occurred with the advent of non-invasive methods for determining BMD, the most prominent of which is DXA 40 . Historically, the lumbar spine and proximal femur were sites that were considered; however, since 2013, the femo ral neck has been recognized as the reference site for epidemiological studies 41 . DXA provided a homogenized, widely utilizable method for calculating BMD as a T score that measures the number of standard deviations from the mean BMD for a 30-year-old man or woman. As a result, in 1994, the WHO produced an operational definition of osteoporosis based on a BMD T score of −2.5 or lower 42 . This score has since become the diagnostic criterion for osteoporosis. A 2006 study showed that there is a 1.5-2.5-fold increase in fracture risk per standard deviation decrease in BMD 21 . Thus, BMD is a good predictive measure of future fractures. By contrast, another measure with equal predictive power is blood pressure as a predictor of future stroke. Both measures have more predictive power than serum cholesterol levels have for cardiovascular disease risk 43 . Although BMD is a good specific predictive measure, the sensitivity for BMD alone in predicting future fractures is <50%, and those in an osteopenic range (T score between −1.0 and −2.5) are still at risk of fracture. The Rotterdam study 44 demonstrated that 44% of women with non-vertebral fractures over a follow-up of 6.8 years had a BMD T score between 0 and −2.5 and that 12% had a completely normal BMD. Another study from the USA showed that only 46% of women who sustained a hip fracture during a 5-year follow-up period had a T score of −2.5 or less for BMD at baseline 45 .
Key points
• The WHo defines osteoporosis as a measurement of BmD that is at least 2.5 standard deviations less than the mean BmD for a 30-year-old man or woman.
• Dual-energy X-ray absorptiometry provides a measure of BmD that can be used to diagnose osteoporosis.
• Central and peripheral quantitative CT can be used to provide measures of bone microarchitecture within a research setting.
• BmD, combined with clinical risk scores, including Fracture Risk Assessment Tool (FRAX), can be used to predict which individuals are at high risk of fracture.
• A gap exists between individuals who are at risk of fracture and those who are receiving treatment and requires closing as a matter of paramount importance.
Denosumab
A fully humanized monoclonal antibody that binds to the receptor activator of rANK ligand, thus blocking the action of rANK ligand. it is delivered via subcutaneous injection as an anti-resorptive agent for the treatment of osteoporosis.
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For the above reasons, 2019 European clinical guidelines have repeated the recommendation of using fracture risk factors (such as fall risk and age 46 ) for identifying those at risk of fracture, as well as a thoracic kyphosis and loss of height of >4 cm (to identify subclinical vertebral fractures) 47 . The low sensitivity of BMD is of high clinical importance and emphasizes that BMD does not take non-skeletal determinants of fracture risk into account. As such, assessment modalities and particularly DXA have a crucial role in identifying at-risk individuals.
Dual energy X-ray absorptiometry Absorptiometry generally relies upon an energy source (for example, photon or X-ray) passing through a test material and a detector that is used to measure the degree of attenuation. This measurement can be compared with a standard control material to calculate the density of the test material. Depending on the properties of a tissue, it will attenuate radiation differently, which allows quantification and separation of different tissues (for example, fat, muscle or bone) from one another. DXA was first described by Mazess in 1981 (reF. 48 ). This method uses two different energy sources (at ~40 KeV and >70 KeV) to allow discrimination between soft tissues and bone and provides increased resolution and precision 49 and a shorter scan time than previous modalities.
DXA has since become the gold-standard measure for BMD owing to the scientific demonstration of a strong correlation with biomechanical bone strength via finite element analysis 50 , a correlation with the clinical outcome of fracture risk 51 and the relatively low radiation burden 52 . Moreover, DXA is also a viable measure for 
Thoracic kyphosis
An S-shaped deformity of the spine that can be precipitated by osteoporotic vertebral fractures.
muscle mass in the assessment of sarcopenia 53 . Notably, DXA measurements alone may be more advantageous than using clinical risk factors (and the related prediction tools) alone when identifying individuals with rare conditions that increase the risk of fracture. However, DXA can be used in conjunction with clinical risk tools (for example, Fracture Risk Assessment Tool (FRAX), which we describe later) in order to more accurately identify those at risk of future fracture.
Quantitative measures derived from 2D densitometry. DXA is a form of 2D densitometry, and the quantitative measurements that can be derived from this method include bone area (cm 2 ), bone mineral content (grams) and areal BMD (grams per cm 2 ). Areal BMD is calculated using pixel by pixel attenuation values of a test material (in this case bone) against a control phantom 54 . Bone area is calculated by summing the pixels that lie within the bone edges, and bone mineral content (in grams) is calculated by multiplying areal BMD and bone area. In 2001, a model was proposed to enhance the comprehension and interpretation of bone densitometry measures in children and adolescents 55 , although this model can also be employed in the understanding of adult bone physiology. The model focuses on three key areas: material BMD, compartmental BMD and total BMD.
Material BMD refers to the mineralization of a small volume of organic bone matrix. A small volume is necessary to exclude marrow, lacunae, canaliculi and osteonic canals from the sample. This measurement can be performed invasively via bone biopsy, or, since 2000 (for cortical bone), via a virtual bone biopsy afforded by high-resolution peripheral quantitative CT (HRpQCT) 56 , which is described later. Compartmental BMD refers to the amount of mineral in the cortical and trabecular compartments and can be assessed by quantitative CT (QCT) methods (central, peripheral and HRpQCT). DXA does not provide measures of compartment BMD, as it is a 2D method. Instead, DXA provides an integrated measure of total BMD, which refers to the entire density of the material within the periosteal envelope.
A limitation of DXA is the aforementioned 2D image that it provides, which limits the ability to measure density (mass per volume), as the depth of the bone cannot be accounted for. This limitation creates a size dependence to measurements, which is problematic in children. Several methods exist to account for these inaccuracies in the use of DXA in children. The methods include calculation of a size-corrected total BMD from the DXA image, bone mineral apparent density 57, 58 and regression methods to take into account the size of the child 59, 60 . Over the past decade, developments in DXA scanning include vertebral fracture assessment using lateral views of the thoracolumbar spine 61 ; hip structural analysis, which utilizes hip cross sections to ascertain bone strength; and trabecular bone score (TBS), which provides a measure of bone quality (rather than the quantity supplied by BMD) and is a surrogate of bone microarchitecture.
Trabecular bone score. TBS is an analytical tool that is used on data acquired using DXA to provide a surrogate measure of bone microarchitecture, providing information on bone structure above and beyond areal BMD 62 . The tool uses a sequence of experimental variograms to quantify variation in grey-level texture between pixels 63 and generate a value that is strongly related to experimental trabecular separation, trabecular number and connective density 64, 65 . The region of interest is usually an anterior-posterior view of the lumbar spine on DXA; a higher TBS is consistent with fracture-resistant bone, and a lower score is consistent with weaker bone 66 . Seemingly, there is an age-dependent variation in TBS, with a relative plateau in mid-life (aged 30-45 years) and a gradual reduction with age 67 . A point of interest is whether the TBS provides any information for the effective prediction of fractures independently of clinical risk factors and areal BMD. A study in a cohort from Manitoba attempted to address this question in women 68 and men 69 and found that, in women, TBS predicted incident fractures (HR 1.36, 95% CI 1.30-1.42; P < 0.001). After adjustment for clinical risk factors and femoral neck areal BMD, the associations were attenuated, although a hazard ratio of 1.18 (95% CI 1.12-1.23) remained for a major osteoporotic fracture 68 . In males, the area under the curve for the prediction of incident major osteoporotic, hip and clinical vertebral fractures was better than that expected by chance alone 69 .
In 2016, a meta-analysis of 14 cohorts was performed to assess the triangular relationship between clinical risk factors, TBS and areal BMD with regard to fracture prediction. The authors found that TBS was partially independently predictive of future major osteoporotic and hip fractures and concluded that the score can have some utility in clinical practice 70 . Through this analysis, a low risk of fracture was defined as a lumbar TBS > 1. 31 , and a high risk of fracture was defined as a TBS < 1. 23 .
Although TBS has been demonstrated to respond to fracture prevention therapy, including bisphosphonates and raloxifene, the percentage change is generally less than that observed in areal BMD 71, 72 . An advantage of TBS is that the tool can be applied to DXA, radiographs, CT and QCT and at any skeletal site, although DXA of the lumbar spine is the most common modality. A potential disadvantage of areal BMD is the artefact caused by degenerative disease (particularly in the spine), which leads to falsely raised BMD levels. However, owing to the methodology, TBS is not affected by degeneration or osteophytes 73 . In addition, TBS is available as a modifier to FRAX online. Potential clinical and technical issues with the accuracy of TBS exist, including artefact generated from image resolution, noise and soft tissues, including adipose tissues 74 . As such, the most accurate measures of TBS will be obtained from individuals with a BMI between 15 and 37 kg/m 2 . In summary, TBS provides additional information regarding bone quality beyond the quantitative measures provided by 2D densitometry. Although DXA is the clinical leader in the image assessment of bone, other scanning modalities have been developed (BoxeS 1, 2) and are used in the research context.
Periosteal envelope
The membrane of connective tissue that surrounds bone. it has two layers, an outer fibrous layer and an inner layer, which plays a crucial role in osteogenesis.
Bone mineral apparent density
An estimated volumetric bone density. Volume is calculated from the dual-energy x-ray absorptiometry (DxA)-assessed bone area by assuming the vertebrae are either a cube or a cylinder. it is a method of reducing the size dependence of DxA measurements and is particularly useful in children.
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Research scanning modalities As previously attested, DXA is the current gold standard for predicting those at high risk of fragility fractures, although this method does have some issues and limitations. These issues include the lack of estimates of compartmental and material BMD, the fact that BMD measurements are size-dependent (as they are calculated using a 2D projection of a 3D structure with no adjustments for object depth) and the fact that the measures of BMD are susceptible to changes in body composition 75 . In order to counter these issues and to provide additional measures of bone structure, morphometry and biomechanics, other, non-DXA scanning techniques have developed and are employed, largely in the research setting. Indeed, elements of bone microarchitecture have been shown to be predictive of incident fracture independent of BMD 76 . These scanning modalities include central QCT, peripheral QCT and HRpQCT.
Central quantitative CT. Central QCT was first developed in the 1970s 77 but came to wider usage in the 1980s 78 . Central QCT is a modality that uses multiple 2D slices, and the central description of the modality refers to the fact that the regions of interest are the lumbar spine (particularly the L1-L3 vertebrae), the proximal femur and peripheral sites, and central QCT also provides a measure of muscle mass 79 . The advantages of central QCT over DXA include the ascertainment of mean volumetric BMD (measured in mg/cm 3 ). This measurement has the advantages of being less sensitive to changes in bone size than areal BMD, and assesses compartmental BMD, bone geometry and biomechanical measures of bone strength 79 . Compared with DXA, the main disadvantages of central QCT are the increased burden of ionizing radiation 80 and the potential issues that exist with confounding by changes in bone marrow fat owing to the majority of scanners being single-energy devices 81 .
Peripheral quantitative CT. The next scanning modality in the QCT family is peripheral QCT, which became commercially available in the 1990s 82 , with the most common model being the XCT 2000 (Stratec, Pforzheim, Germany). This method takes 2D slices (1-2 mm thick) of the radius and tibia, which (owing to the very low radiation burden) can be performed at multiple sites along the bone. This modality provides not only valuable data on volumetric BMD, compartmental BMD, bone geometry and bone strength but also muscle measures including cross-sectional area and muscle density 83 . Measurements of muscle provide the opportunity to calculate a bone to muscle ratio, which is relevant when considering some hypotheses for bone strength and loading (for example, the mechanostat theory 84 ).
High-resolution peripheral quantitative CT. The most recently developed QCT scanning modality is HRpQCT (XtremeCT, Scanco Medical, Bruttisellen, Switzerland), which allows multiple 2D slices (most commonly of the radius or tibia) to be recreated into a 3D virtual bone biopsy. The enhanced spatial resolution afforded by this modality is in excess of that provided by standard peripheral QCT, QCT or MRI 85 . HRpQCT imparts a low dose of radiation (<3 μSv), and owing to semi-automated contouring and segmentation of tissue, this method provides data on densitometry, morphometry, microarchitecture and biomechanical measures (including stiffness and elastic modulus) through finite element analysis 86, 87 .
Non-dual-energy X-ray absorptiometry scanning in clinical practice. A recent prospective study by the Bone Microarchitecture Consortium found that HRpQCT measurements (particularly peripheral skeleton failure load, which is the prediction of the external force required to cause failure of the bone) were statistically significantly associated with future risk of fracture over ~4.5-year follow-up after adjustment for BMD 76 . However, it should be emphasized that, although the above non-DXA scanning modalities provide valuable data to drive forward densitometric research, they are not currently used in clinical practice owing to a lack of routine accessibility. Whilst quantitative ultrasonography was used extensively in research studies, particularly in the 1990s, the practical limitations of this technology and inferior ability to predict individual fracture status (compared with DXA) led to diminishing use and application. Quantitative ultrasonography also lacks a coherent standardization across different models and instruments of algorithmic data resolution and resultant reported parameters 88 . This method does, however, have a potential utility in low-resource settings where DXA is unavailable. Interestingly, MRI has also been used to assess bone densitometry and has future potential in terms of usage in the clinical or research settings 89 .
Box 1 | Microindentation
Stiffness is the ability of a structure to resist deformation. When subjected to a particular load, a stiffer bone will deform less than a softer, more compliant bone. The increasing porosity of bone with age leads to reduced stiffness and, thus, increased risk of fracture 115 . measurements of BmD do not capture bone porosity, and so other methods have been developed to assess this element of fracture risk.
microindentation is a novel methodology that involves inserting a probe through the skin and down onto the bone surface at a particular anatomical site (for example, the anterior midtibia) to measure the stiffness and toughness of a bone. Bone material Strength Index (BmSi) is measured by comparing the indentation distance of the bone with a reference standard calibration material. on the surface of the bone, the probe induces microfractures; the weaker the bone is, the greater the distance that the probe extends into the bone and the lower the BmSi 116 . microindentation has been shown to distinguish between degrees of fracture risk [116] [117] [118] , between individuals with osteoporosis and controls 119 and between individuals at risk of atypical femoral fracture and controls 120 . However, the technique has also been associated with areal BmD in isolation without associations with fracture risk 121 . This method has limitations, as it tests the tibia, which is an uncommon site of fragility fracture. moreover, the invasive nature of microindentation means that it might be less likely to be tolerated in clinical practice than imaging modalities. Regarding the latter, a 2018 study has sought to address this in a large cohort of 345 Australian males, in whom the procedure was well tolerated, although 56 individuals were contraindicated by the presence of excessive soft tissues in the midtibial zone 122 . overall, it is estimated that ~1,500 individuals have had the procedure globally, with 2 reported episodes of adverse events; 1 was a mild skin infection and 1 was a reaction to local anaesthetic 122 . In summary, microindentation is a technique that shows promise and seeks to identify individuals who are at risk of fracture owing to bone weakness, who are potentially missed by measurement of BmD alone 123 . NATuRe RevIeWS | EndOCRInOlOgy
Fracture prediction tools
In clinical practice, imaging (particularly DXA) is used not in isolation but together with clinical risk factors for fractures 47 . These risk factors can each be assessed in isolation but have also been incorporated into usable tools for assessing fracture risk.
Fracture Risk Assessment Tool. The WHO definition of osteoporosis was used to determine the threshold for treatment, but, although the definition held at a population level, many individuals sustain fractures with BMD T scores that are closer to 0. This observation has led to the development of fracture risk prediction tools, including FRAX, QFracture and Garvan.
The first clinical risk score was developed as a proof of concept in 2006 (reF.
90
). This algorithm was produced from data on the General Practitioner Research Database and provided a measure of future fracture risk. However, there are two important limitations in the use of this tool that are both based around the absence of BMD from the algorithm (owing to the primary care nature of the data collected). The first limitation is that it seemed counterintuitive to exclude BMD as an important parameter in the prediction of fracture. The second limitation is that the medical trials designed to prevent fragility fractures had been performed in individuals with low BMD and, thus, it seemed a non-sequitur to ask clinicians to base their decision to treat on an alternative yard stick.
The next (and now most widely adopted) of the fracture prediction tools was FRAX, which was published in 2008 (reF. 91 ). The FRAX tool was developed via systematic meta-analyses of primary data from 9 global, geographically spread cohort studies and then validated on data from a further 11 cohort studies. Key principles in the development of the FRAX tool were that any variable included in the algorithm (and thus the clinical tool) should be intuitively linked to fracture, readily clinically available, at least partly independent of BMD and associated with a fracture risk that might be reversible through pharmacological treatment 92 . The clinical parameters incorporated into the FRAX tool include age, sex, weight, height, previous fracture, parental hip fracture, current smoking status, glucocorticoid usage, the presence of rheumatoid arthritis, secondary causes of osteoporosis, alcohol consumption and BMD (though the last can be excluded in underresourced settings, which preclude the use of DXA). These clinical parameters are used to provide a separate 10-year probability of any osteoporotic fracture and hip fracture. The tool, which is available in over 30 languages, has been made freely available via the FRAX website and is used for an estimated 225,000 calculations per month 93 , although paper formats are available in under-resourced settings. Fracture incidence is known to differ across the globe 11 , and FRAX has the ability to adjust according to global region; in 2006, 80% of the global population was covered by the FRAX tool 93 . The limitations of FRAX include the unquantified glucocorticoid exposure, which is recorded as a binary yes-no, and the omission of lumbar spine BMD, TBS, hip axis length and falls history. Methods to account for some of these considerations have now been documented or implemented through adjunctive algorithms or national guidelines 93 . For example, diabetes mellitus increases the risk of fracture but is not directly included in the FRAX tool. Different approaches have been used to circumvent the limitations of the tool including incorporation of TBS, ticking the rheumatoid arthritis button (on the FRAX website), increasing the age input by 10 years and reducing femoral neck BMD T score by 0.5 standard deviations (for example, a T score of −1.75 became −2.25) 94 . A further example of FRAX tool refinement is that of spine-hip discordance, which uses the difference between lumbar spine and femoral neck BMD T scores to improve fracture prediction by using the following rule: "increase or decrease the FRAX estimate for major osteoporotic fracture by one-tenth for each rounded BMD T score difference between lumbar spine and femoral neck" 95 .
QFracture. The QFracture tool was published in 2009
(reF. 96 ). This tool was derived using Cox proportional hazards models on the data of 2 million individuals aged between 30 and 85 years in the General Practitioner Research Database in the UK. The same data set was then used to validate the tool. Consequently, QFracture is primarily applicable to the UK population, and although it is only calibrated on hip fracture, the tool does provide estimated incidences of hip, forearm, spinal
Box 2 | Biochemical markers of bone turnover
Bone turnover is characterized by bone formation and bone resorption. Biochemical bone turnover markers (BTms) have been discovered and developed to capture measurements of these two activities. International expert groups in the fields of clinical chemistry and osteoporosis have come to a consensus that the amino-terminal propeptide of type I procollagen (PINP) and the carboxy-terminal telopeptide of type I collagen (CTX-I) should be the markers for bone formation and bone resorption, respectively 124 . CTX-I is a product of the breakdown of type I collagen and has a strong circadian rhythm, which necessitates early morning blood collection. PINP is formed from the post-translational cleavage of type 1 procollagen and has no circadian rhythm; however, owing to obvious practicalities, it is usually collected contemporaneously with CTX-I (unpublished observations; N.R.F., e.m.C., K.W., N.C.H., e.m.D. and C.C.).
Pre-analytical variability of BTms is an important consideration, with circadian variation, seasonal variation, physical activity and food intake being examples of modifiable determinants 124 . The last of these is due to the intestinal induction of glucagon-like peptide 2, which stimulates a post-prandial decrease in CTX-I. less modifiable determinants include age, sex, hormone levels (including menopausal changes and endocrine disorders) and the effect of certain medications (for example, corticosteroids, anti-epileptics and heparin) 124 . BTms appear to be predictive of fracture (independently of age, BmD and prior fracture) in particular demographic groups, including postmenopausal women and elderly women [125] [126] [127] . moreover, they are associated largely with major osteoporotic fractures and can be predictive over a relatively short follow-up period (<5 years) (as opposed to 10-year prediction probabilities by Fracture Risk Assessment Tool (FRAX)). The association with future fractures is probably due to the link between a high turnover state and lower BmD and poor quality bone microarchitecture 128 . BTms can be employed to monitor the response to fracture-protective therapies and are often used in the context of bone-forming agents such as teriparatide 27 . 2019 guidelines have also noted their potential utility in predicting fractures when BmD is unavailable 47 .
In conclusion, BTms appear to be a useful adjunct to traditional methods of identifying those at risk of fracture (in particular, postmenopausal women) and may have an additional role in monitoring response to treatments.
www.nature.com/nrendo and shoulder fracture. As in the 2006 tool, BMD is not included, and QFracture is therefore subject to the same limitations. The number of risk factors was extended in 2012, on the basis of National Institute for Health and Clinical Excellence guidance on the risk assessment for osteoporosis, to include history of previous fracture, presence of epilepsy (or anticonvulsant use), ethnicity and the presence of type 1 diabetes mellitus.
The current list of clinical parameters included in the QFracture tool includes age, sex, ethnicity, smoking status, alcohol use, type 1 or type 2 diabetes mellitus, parental history of hip fracture and/or osteoporosis, nursing or care home residence, history of prior osteoporotic (wrist, spine, hip or shoulder) fracture, history of falls, dementia, cancer, obstructive airways disease (asthma or chronic obstructive pulmonary disease), cardiovascular disease, chronic liver disease; chronic kidney disease, Parkinson disease, rheumatoid arthritis or systemic lupus erythematosus, gastrointestinal malabsorption, epilepsy (or use of anticonvulsants), use of antidepressants, use of corticosteroids, and BMI. The following additional factors are used for only women: oestro genonly hormone replacement therapy and endocrine problems (including thyrotoxicosis, primary or secondary hyperparathyroidism and Cushing syndrome).
Garvan. The Garvan fracture prediction tool was developed on the basis of ~2,500 members of the Australian Dubbo Osteoporosis Epidemiology Study (DOES) 97 . This tool does not include rheumatoid arthritis, secondary osteoporosis, steroid use, smoking, alcohol, parental hip fracture or secondary osteoporosis in the parameters that are entered into the risk calculation. However, the Garvan tool does provide a novel angle through the inclusion of the number of fractures since the age of 50 years and the number of falls in the previous year.
The tool previously provided a risk of fracture at a large number of sites (including distal femur, pelvis, patella, proximal and distal tibia and fibula, ribs and sternum, hands and feet) but has now focused down to a 5-year and 10-year percentage risk of hip fracture and any osteoporotic and/or fragility fracture 97 . The potential disadvantages of the Garvan risk score are that it is based on a single Australia cohort (which could limit its wider applicability) and it does not take the competing hazard of death into account.
Prediction tools worldwide. FRAX has been more widely adopted globally than QFracture or Garvan. In 2016, FRAX had been incorporated into 120 guidelines worldwide, and it is widely incorporated into DXA software and primary care computer systems 98 . When incorporated into these recommendations, FRAX is either used with a fixed FRAX intervention threshold (with or without BMD) or as a gateway to an assessment that includes age-dependent intervention thresholds 93 . The use of fixed thresholds for intervention is usually incorporated with a measure of BMD and a history of prior fragility fracture and is very simple to use in a clinical setting. However, the simplicity of the use of fixed thresholds for intervention masks the issue demonstrated in Fig. 2 , which depicts the FRAX percentage 10-year risk of major osteoporotic fracture against age for men and women with a history of prior fragility fracture and individuals with a BMD T score of −2.5. Notably, the fixed threshold for BMD T score results in a minimal proportion of women aged between 80 and 90 years being treated and in undertreatment of the whole population 93 . The above observation is clearly unsatisfactory and counterintuitive to good clinical practice. For this reason, in the UK, the National Osteoporosis Group Guidelines employs a combination of age-dependent and fixed thresholds to guide further investigation (via DXA) and intervention 99, 100 . To expand on this, the intervention thresholds for the initiation of pharmaco logical therapy are, for women with a history of prior fragility fracture (with no requirement for further assessment), age-dependent thresholds until the age of 70 years and fixed thresholds thereafter.
The National Osteoporosis Foundation guidelines in the USA suggest that pharmacological therapy should be initiated in those with a prior history of hip or vertebral fracture and in individuals with a T score of -2.5 or less 101 . Additionally, postmenopausal women and men ≥50 years with T scores in an osteopenic range (that is, -2.5 to -1.0) and a US-adapted FRAX score of ≥3% risk of hip fracture and ≥20% risk of major osteoporotic fracture should receive treatment. Here, the reference to a US-adapted FRAX score indicates that National Osteoporosis Foundation guidelines have been calibrated according to USA fracture rates and mortality. The American College of Rheumatology (ACR) 102 and Scottish Intercollegiate Guidelines Network (SIGN) guidance use FRAX risk to direct BMD screening and intervention thresholds 103 . Notably, the SIGN guidelines use fracture clinical risk factors as an initial assessment, followed by BMD assessment; a BMD T score of -2.5 or 
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NATuRe RevIeWS | EndOCRInOlOgy less is the gateway to treatment, which is an approach that could potentially widen the treatment gap 103 . European guidance regarding thresholds for pharmacological intervention in postmenopausal women recommend the use of a FRAX-based approach to clinical decision-making and that women over the age of 65 years with a history of prior fragility fracture are considered for treatment without any further assessment 47 . Younger postmenopausal women should undergo an additional assessment of BMD. This recent guideline also recommended that age-dependent thresholds are clinically appropriate and cost-effective in their identification of those requiring treatment 47 . After FRAX was devised and validated, it was important to examine whether the test had a discernible effect on fracture rates within the context of randomized controlled trials, which are described below.
The SCOOP trial
The WHO recommendations for screening (Box 3) for fragility fractures include the assessment of fracture risk into high-risk, medium-risk or low-risk groups; highrisk individuals are considered for treatment, low-risk individuals are not recommended for treatment, and medium-risk individuals are further assessed with a measurement of BMD 104 . The Screening of Older Women for the Prevention of Fractures (SCOOP) trial was designed as a pragmatic, unblinded, randomized controlled trial of women aged 70-85 years. It was based in seven centres in the UK including Birmingham, Bristol, Manchester, Norwich, Sheffield, Southampton and York, from which 12,483 participants were recruited.
Aims and rationale. The aim of the study was to examine the effectiveness and cost-effectiveness of a community-based screening programme to decrease fragility fractures in older women and thereby address the aforementioned treatment gap in this population. The structure of the study is depicted in Fig. 3 .
Previous trials of population screening for osteoporosis have been undertaken, including one based in a popu lation of postmenopausal women, which was started in the 1990s and reported in 2010 (reF. 105 ) and reported that screening marginally increased the usage In order to contextualize the developments in osteoporosis and fragility fracture, it is interesting to review the condition as a case study in light of the Wilson-Jungner criteria for the validity of screening 129 . The criteria address the condition itself, the test for that condition, subsequent treatment and feasibility of screening. osteoporosis amply satisfies the considerations with regard to the condition, being common, well-defined and with its epidemiology, natural history and costs thoroughly characterized 1, 13 . osteoporosis is readily detected through the use of a validated, reliable and widely available technique, dual-energy X-ray absorptiometry, satisfying the second criterion. There is a wide range of effective treatments for osteoporosis, which have been shown to reduce fracture risk, and given the inevitable decline in BmD with age, earlier intervention before fractures have occurred, is fully justified. Historically, the field has focused on an opportunistic case-find approach to ascertainment of disease, but with the results of the Screening of older Women for the Prevention of Fractures (SCooP) trial, the last point considered by Wilson and Jungner (the use of a population-screening approach) is now supported. Owing to the pragmatic study nature, double-blinding was not feasible; however, research staff acquiring hospital fracture data were blinded to the participant study arm. A total of 12,483 participants were randomized to either the control arm or the screening arm, constituting 59,401 person-years of observation. The control arm comprised individuals receiving usual care (provided in primary care); individuals in the screening arm had their 10-year probability of fracture calculated using FRAX. Those at moderate to high risk underwent dual-energy X-ray absorptiometry (DXA) to calculate BMD. Treatment decisions were made in primary care on the basis of the above findings. In SCOOP, the primary outcome measure was the proportion of individuals sustaining fragility fractures (that is, not excluding fractures of the skull, hand, foot and nose) in each group. Secondary outcomes included the proportions of all fractures, hip fracture rate, cost-effectiveness, mortality and EQ-5D (a healthcare quality assessment tool) in each group and a qualitative evaluation of participant acceptability. Effectiveness data analysis was performed using Cox's proportional hazards models. Linear models were used for quality of life analyses, and all relevant analyses were performed on an intention to treat basis. Economic analyses were obtained from a tax payer's perspective according to the costs to the National Health Service (NHS). A qualitative exploration of acceptability and adherence was performed. Data in Fig. 3 were first presented in reF. 130 .
www.nature.com/nrendo of osteoporosis treatments and reduced fracture incidence. In addition, a more recent randomized controlled trial of primary care-based screening was reported in 2012 (reF.
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), which found that screening for osteoporosis increased prescription of osteoporosis medication at 6 months (OR 2.24, 95% CI 1. 16-4.33) . The primary difference between these studies and SCOOP is that, with SCOOP, the primary outcome was fracture incidence and not treatment uptake.
Results. The study population comprised women aged between 70 and 85 years, who were assigned to either a screening arm (those found to have moderate or high risk of fracture by FRAX underwent further assessment of BMD) or a control arm (receiving usual care, provided in a primary care setting; Fig. 3 ). The key effectiveness findings of the SCOOP study were published in 2018 (reF. 107 ), although there were no significant differences in the primary outcome measure of all osteoporosis-related fractures between the screening arm and control arm (HR 0.94, 95% CI 0.85-1.03; P = 0.178) or the rate of all clinical fractures (HR 0.94, 95% CI 0.86-1.03; P = 0.83), as shown in TABle 1. However, in a pre-specified analysis, the rate of hip fracture was statistically significantly lower in the screening arm (HR 0.72, 95% CI 0.59-0.89; P = 0.002).
In terms of numbers needed to treat, the absolute size in hip fracture rate reduction was 0.9%, which means that 111 women aged 70-85 years would need to be screened in order to avert a single hip fracture. Notably, the reduced risks that were observed in SCOOP were strongly affected by the efficacy of the currently available treatments, and as the efficacy of treatments rise, the risk of fracture will probably reduce. Osteoporosis medication use was higher in the screening group than in controls at the end of year 1 (15% versus 4%), with medication use being particularly high in the highrisk group at the 6-month time point (78%). There was no difference in mortality, anxiety or quality of life outcomes between the two groups.
Of the 6,233 participants randomized to the screening arm, 3,049 (49%) reached criteria for subsequent DXA assessment of BMD and 898 (14%) received treatment with osteoporosis medication by 6 months. At 1 year, 953 (15%) of individuals in the screening arm had received at least one treatment with osteoporosis medication, and this proportion remained relatively stable, between 13% and 15%, over the course of the 4 years of follow-up. In the control arm, 264 (4%) received an osteoporosis medication by 1 year, but this number steadily rose to 633 (10%) at 4 years. In terms of the fractures, across both arms, there were 1,975 fragility fractures, which affected 1,657 participants (13% of those randomized). The most common sites were distal forearm and hip. The qualitative work performed as part of the SCOOP study demonstrated that the screening was acceptable to women 108 .
Trial limitations. The limitations of the SCOOP study include the fact that, of the eligible population, only onethird of individuals participated and that there appeared to be selection bias towards healthy individuals, with mortality lower than expected (9% observed versus 19% expected), and higher educational and socio-economic status. Relatively few participants were at high risk of fractures (14% observed versus 20-40% expected); however, the rates of fracture were higher than predicted. It is also possible that general practitioners may have been more likely to treat individuals in the control arm owing to the contamination of their involvement in an osteoporosis-related study.
Whether this model of population screening is eligible for national roll-out depends not only on efficacy but also on cost-effectiveness and the feasibility within the constraints of the public purse.
Cost-effectiveness analysis. Since the advent of the SCOOP study, there have been two helpful systematic reviews of cost-effectiveness in the field of fragility fractures. The first found that health economic models 109 , whereas the second purports to the costeffectiveness of drug therapy for osteoporosis in postmenopausal women 110 . The latter review found that osteoporosis medications were cost-effective in women aged 60 years and over, particularly if additional risk factors for fracture were present 110 . Given that the SCOOP study was performed in the UK, the subsequent health economic analyses were performed according to this geography. A three-level EQ-SD (an instrument used to assess health-related quality of life) assessment provides a measure of qualityadjusted life-years (QALYs) 111 . The costs of DXA scans, clinical review, primary care consultations and written notifications in SCOOP were calculated locally through dialogue with the general practitioners involved. Inpatient, outpatient and emergency department data sets were run though a Healthcare Resource Group 4 + reference costs grouper 112 . The key heath economic finding from the SCOOP study was that the screening model trialled was costeffective. There was an increase of 0.0237 QALYs for participants in the active arm of the trial, with an £2,772 incremental cost per QALY in the screening arm versus the control arm 113 . The screening intervention also reduced fractures; the cost per osteoporosis-related fracture prevented was £4,478, and the cost per hip fracture prevented via the screening programme was £7,694. The cost-effectiveness acceptability curves suggested that there was a 93% probability of the screening intervention being cost-effective, at a value of >£20,000 per QALY, concluding that the screening programme was a highly cost-effective strategy 113 (Fig. 4) .
A post hoc analysis focusing on those who are at high risk of fracture was published in 2018 (reF. 114 ), which aimed to examine possible interactions between screening efficacy and baseline FRAX 10-year risk of fracture and fracture outcomes. Interactions were observed between history of prior fracture, parental fracture history, smoking and the efficacy of screening 114 . Importantly, in individuals at highest risk of fracture, the estimated reduction in hip fracture risk was >50% 114 (Fig. 5) . Despite the limitation that not all participants included in the SCOOP trial had BMD measurements at baseline or during follow-up, the conclusion of the post hoc analysis was that those women who are at high risk of hip fracture on the basis of FRAX probability are responsive to appropriate osteoporosis management 114 . The greater reduction in hip fracture risk in those who had higher baseline risk strongly suggests that treatment rather than other factors explained the observed effect.
The effect of screening was greatest in those with the risk factors of prior history of fracture and parental history of fracture 114 . Of note, prior history of fracture and parental history of fracture respresent the most relevant clinical risk factors. These factors might have had some bearing on persistence and uptake of medications by study participants. The presence of these two factors might also have driven increased treatment rates in the screening arm.
In summary, if the SCOOP screening strategy is adopted in the UK for 70-85-year-old women (assuming the size of this population is similar to that estimated in 2016 (3.7 million)), it could prevent 8,000 hip fractures each year, would be cost-effective in doing so and would result in considerably better treatment adherence at 5 years of follow-up.
Conclusions
The past 20 years has seen a concerted shift from the definition of osteoporosis based on BMD to the effective identification (and therefore treatment) of individuals at risk of fracture. Fracture prediction algorithms such as FRAX and imaging modalities such as DXA present usable and highly effective tools to identify individuals at risk. Moreover, developments in research scanning have enhanced our scientific understanding of bone microarchitecture. As recent trial evidence clearly shows, . Figure reproduced with permission from reF.
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www.nature.com/nrendo primary prevention of osteoporotic fragility fractures is not only effective but also cost-effective 107, 113, 114 . Despite this, there is still a concerning majority of at-risk individuals who are missed through a lack of assessment, and there must therefore be a concerted effort to address this issue if we are to close the ever-widening treatment gap. In the future, novel methods of fragility assessment (BoxeS 1,2) might go some way to address this need.
